Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patientsDavid M Brown
Vitreoretinal Consultants, Houston, Texas 77030, USA
Am J Ophthalmol 144:627-37. 2007
....
Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end pointDavid M Brown
Retina Consultants of Houston, The Methodist Hospital, Houston, Texas, USA
Ophthalmology 120:349-54. 2013
....
- Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration
David M Brown
Retina Consultants of Houston, The Methodist Hospital, Houston, Texas 77030, USA
Retina 33:23-34. 2013
..To investigate if anatomical characteristics of eyes undergoing ranibizumab therapy were predictive of best-corrected visual acuity (BCVA) outcomes over 2 years...
- Long-term stability of circumferential silicone sponge scleral buckling exoplants
David M Brown
The Methodist Hospital, Houston, Texas 77030, USA
Retina 26:645-9. 2006
..This study was undertaken to assess the long-term stability of 360 degrees circumferentially placed 3 x 5 mm silicone sponge exoplants...
- Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study
David M Brown
Retina Consultants of Houston, The Methodist Hospital, Houston, Texas 77030, USA
Ophthalmology 117:1124-1133.e1. 2010
..To assess the efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema after central retinal vein occlusion (CRVO)...
- Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration
David M Brown
Retina Consultants of Houston, The Methodist Hospital, Houston, Texas, USA
Ophthalmology 118:1089-97. 2011
..To evaluate the biologic effects and safety of vascular endothelial growth factor (VEGF) Trap-Eye during a 12-week fixed-dosing period in patients with neovascular (wet) age-related macular degeneration (AMD)...
- Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study
David M Brown
Retinal Consultants of Houston, Houston, Texas, USA
Ophthalmology 118:1594-602. 2011
..Assess 12-month efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema after branch retinal vein occlusion (BRVO)...
- Ranibizumab versus verteporfin for neovascular age-related macular degeneration
David M Brown
Vitreoretinal Consultants, Methodist Hospital, Houston, TX 77030, USA
N Engl J Med 355:1432-44. 2006
....
- Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study
David M Brown
Vitreoretinal Consultants, Methodist Hospital, Houston, Texas 77030, USA
Ophthalmology 116:57-65.e5. 2009
....
- Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study
David M Brown
Retina Consultants of Houston, The Methodist Hospital, Houston, TX, USA
Am J Ophthalmol 155:429-437.e7. 2013
..To evaluate intravitreal aflibercept injections (IAI; also called VEGF Trap-Eye) for patients with macular edema secondary to central retinal vein occlusion (CRVO)...
Use of nepafenac (Nevanac) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injectionsEric Chen
Retina Consultants of Houston, The Methodist Hospital, Houston, TX, USA
Clin Ophthalmol 4:1249-52. 2010
..The purpose of this study is to determine the efficacy of combining topical nepafenac with monthly intravitreal injections of ranibizumab or bevacizumab in the treatment of recalcitrant exudative macular degeneration...
- Endophthalmitis after intravitreal injection: the importance of viridans streptococci
Eric Chen
Retina Consultants of Houston, The Methodist Hospital, Houston, Texas, USA
Retina 31:1525-33. 2011
..To determine the rate of postinjection endophthalmitis and compare microbial etiology and outcomes in office-based injection-related endophthalmitis versus those acquired after operating room procedures...
- Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the "flying saucer" sign)
Eric Chen
Retina Consultants of Houston, The Methodist Hospital, Houston, Texas, USA
Clin Ophthalmol 4:1151-8. 2010
..Patients receiving HCQ were evaluated with spectral domain optical coherence tomography (SD OCT) to assess the feasibility of identifying HCQ retinopathy at an early stage...
- Selected clinical comparisons of spectral domain and time domain optical coherence tomography
Damien M Luviano
Greater Houston Retina Research Center, Vitreoretinal Consultants, Houston, Texas, USA
Ophthalmic Surg Lasers Imaging 40:325-8. 2009
..In each case, the improved images provided by SD-OCT changed either the management of the patient or the counseling of their disease process...
- Lucentis using Visudyne study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration
Eric Chen
Retina Consultants of Houston, Texas, USA
Clin Ophthalmol 4:1073-9. 2010
..This pilot study was designed to determine the threshold fluence dose of vPDT (the dose required to demonstrate an effect on choroidal perfusion) combined with ranibizumab...
- Ranibizumab for neovascular age-related macular degeneration
Philip J Rosenfeld
Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
N Engl J Med 355:1419-31. 2006
..Ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--has been evaluated for the treatment of neovascular age-related macular degeneration...
- Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results
Peter K Kaiser
Cole Eye Institute, Cleveland, OH 44195, USA
Am J Ophthalmol 144:850-857. 2007
....
- Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1
Carl D Regillo
Retina Service, Wills Eye Institute, 840 Walnut Street, Philadelphia, PA 19107, USA
Am J Ophthalmol 145:239-248. 2008
..To evaluate the efficacy and safety of ranibizumab administered monthly for three months and then quarterly in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)...
- Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema
David J Browning
Jaeb Center for Health Research, 15310 Amberly Drive, Suite 350, Tampa, FL 33647, USA
Ophthalmology 114:525-36. 2007
..To compare optical coherence tomography (OCT)-measured retinal thickness and visual acuity in eyes with diabetic macular edema (DME) both before and after macular laser photocoagulation...
- Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema
David J Browning
Jaeb Center for Health Research, 15310 Amberly Drive, Suite 350, Tampa, FL 33647, USA
Ophthalmology 115:1366-71, 1371.e1. 2008
..To evaluate optical coherence tomography (OCT) measurements and methods of analysis of OCT data in studies of diabetic macular edema (DME)...
- Cystoid macular edema secondary to albumin-bound paclitaxel therapy
Stacy V Smith
Arch Ophthalmol 126:1605-6. 2008
